Clinical Trials in Ohio

Showing 13001-13020 of 17,983 trials

Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body Weight

NCT02635698

Compare percent change in loss of body weight between the OPTIFAST program and a food-based energy-deficit program

Société des Produits Nestlé (SPN)330 participantsStarted Nov 2015

Anchorage, Alaska, United States • Schaumburg, Illinois, United States • Ann Arbor, Michigan, United States +6 more locations

COMPLETEDPhase 132 miles

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

NCT01340846

GSK2118436 is an orally administered, potent and selective small molecule BRAF inhibitor that is being developed for the treatment of BRAF mutation-positive tumors. This is a 4-part study (in 4 separate cohorts of subjects) designed to examine the interaction potential of GSK2118436, either as a perpetrator (i.e., effect of GSK2118436 on warfarin; Part A) or victim (i.e., effect of other drugs on GSK2118436; Part B: ketoconazole and Part C: gemfibrozil), as well as to evaluate the single and repeat dose pharmacokinetic parameters of GSK2118436 (Part D). A sufficient number of subjects will be screened to obtain approximately 12 evaluable subjects each for Part A, Part B, Part C and Part D. Following completion of this study, subjects may continue dosing with GSK2118436 in the roll-over study, Protocol BRF114144.

Cancer

GlaxoSmithKline48 participantsStarted Sep 2012

Scottsdale, Arizona, United States • Sarasota, Florida, United States • Detroit, Michigan, United States +8 more locations

Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body Weight

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Find Trials by Condition in Ohio

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

VEG111485: A QTc Study of Pazopanib

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Natural Evolution of AV Conduction Disorders in Patients Implanted With Cardiac Pacemakers

Extended Follow-Up After Islet Transplantation in T1D

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (F.A.M.E.)